Compass Pathways: Still A Buy, But The Exit Just Got Complicated (NASDAQ:CMPS)
· seekingalpha.com
Compass Pathways stays a Buy, but Eli Lilly’s AtaiBeckley deal raises competition and funding risks. Click to get key timelines, cash runway & strategy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...